BBC World Service

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Retrieved on: 
Wednesday, April 3, 2024
Patient, LLP, Prescription, IBD, Investor's Business Daily, Amylyx Pharmaceuticals, Advertising, Court, BBC World Service, Evercore, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Bragar Eagel & Squire, P.C. Is Investigating Trupanion, and Apple and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, April 3, 2024
Maker, Apple Inc., AAPL, Attention, Trupanion, IPhone, News, Digital Markets Act, P.C, Investor's Business Daily, DMA, BBC World Service, Mobile phone

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Trupanion Inc. (NASDAQ: TRUP), and Apple Inc. (NASDAQ: AAPL).

Key Points: 
  • NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Trupanion Inc. (NASDAQ: TRUP), and Apple Inc. (NASDAQ: AAPL).
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • Then on March 21, 2024, Investor's Business Daily published a report titled "Apple Stock Drops As Justice Department Sues iPhone Maker."

APPLE ALERT: Bragar Eagel & Squire, P.C. is Investigating Apple Inc. on Behalf of Apple Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 30, 2024
Maker, Apple Inc., AAPL, Attention, IPhone, Telephone, News, Digital Markets Act, P.C, Investor's Business Daily, DMA, BBC World Service, Mobile phone

NEW YORK, March 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Apple Inc. (“Apple” or the “Company”) (NASDAQ: AAPL) on behalf of Apple stockholders.

Key Points: 
  • NEW YORK, March 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Apple Inc. (“Apple” or the “Company”) (NASDAQ: AAPL) on behalf of Apple stockholders.
  • Our investigation concerns whether Apple has violated the federal securities laws and/or engaged in other unlawful business practices.
  • The focus of this investigation is whether Apple issued false and/or misleading statements and/or failed to disclose information relevant to investors.
  • Then on March 21, 2024, Investor's Business Daily published a report titled "Apple Stock Drops As Justice Department Sues iPhone Maker."

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NYCB, Amylyx, Xponential, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 30, 2024
SSS, Signature, Vii, Apoptosis, ALS, Patient, AUV, Bloomberg Businessweek, ACL, Food and Drug Administration, Defendant, AMX0035, Amyotrophy, Sale, News, Dermatology, Prescription, New York Community Bank, NYCB, IBD, Complaint, P.C, Geisler, Investor's Business Daily, Assumption, Confidentiality, Amylyx Pharmaceuticals, Injury, Category, Dentist, FDA, BBC World Service, Evercore, Food, Pharmaceutical industry

NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.

Key Points: 
  • NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.
  • NYCB is engaged in several national businesses, including multi-family lending, mortgage originations and servicing, and warehouse lending.
  • On January 31, 2024, before the market opened, NYCB announced its fiscal fourth quarter 2023 financial results.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Retrieved on: 
Thursday, March 28, 2024
Patient, LLP, Prescription, IBD, Investor's Business Daily, Amylyx Pharmaceuticals, Advertising, Court, BBC World Service, Evercore, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors

Retrieved on: 
Wednesday, March 27, 2024
Research, TPD, Cannabis, Investor's Business Daily, OTC, HYLA, CAVE, BBC World Service, Drug

This initiative is set to position EDXC and its HYLA division at the forefront of the rapidly evolving cannabis and plant-based wellness landscapes.

Key Points: 
  • This initiative is set to position EDXC and its HYLA division at the forefront of the rapidly evolving cannabis and plant-based wellness landscapes.
  • The landmark legalization of cannabis in Germany, highlighted by Investor's Business Daily, heralds a transformative era in the European market, ushering in unparalleled opportunities for forward-thinking companies like Endexx Corporation.
  • Moreover, Endexx Corporation has commenced TPD registration in Europe, further cementing its market presence and paving the way for expanded distribution throughout the continent.
  • With a commitment to sustainability, wellness, and innovation, Endexx Corporation invests in research and development, strategic marketing, and global expansion efforts to leverage evolving market dynamics and regulatory landscapes.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 26, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

APPLE ALERT: Bragar Eagel & Squire, P.C. is Investigating Apple Inc. on Behalf of Apple Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 23, 2024
Maker, Apple Inc., AAPL, Attention, IPhone, Telephone, News, Digital Markets Act, P.C, Investor's Business Daily, DMA, BBC World Service, Mobile phone

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Apple Inc. (“Apple” or the “Company”) (NASDAQ: AAPL) on behalf of Apple stockholders.

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Apple Inc. (“Apple” or the “Company”) (NASDAQ: AAPL) on behalf of Apple stockholders.
  • Our investigation concerns whether Apple has violated the federal securities laws and/or engaged in other unlawful business practices.
  • The focus of this investigation is whether Apple issued false and/or misleading statements and/or failed to disclose information relevant to investors.
  • Then on March 21, 2024, Investor's Business Daily published a report titled "Apple Stock Drops As Justice Department Sues iPhone Maker."

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 22, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Retrieved on: 
Tuesday, March 19, 2024
Patient, LLP, Prescription, IBD, Investor's Business Daily, Amylyx Pharmaceuticals, Advertising, Court, BBC World Service, Evercore, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).